Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data
Epstein S, Xia Z, Lee AJ, Dahl M, Edwards K, Levit E, Longbrake EE, Perrone C, Kavak K, Weinstock-Guttman B, Diallo F, Ricci A, Riley CS, De Jager PL, Farber R, Wesley SF, Collaborative M. Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data. Multiple Sclerosis And Related Disorders 2021, 57: 103433. PMID: 34923427, PMCID: PMC8638239, DOI: 10.1016/j.msard.2021.103433.Peer-Reviewed Original ResearchMeSH KeywordsCOVID-19COVID-19 VaccinesCross-Sectional StudiesHumansNeuroinflammatory DiseasesSARS-CoV-2VaccinationConceptsNeuromyelitis optica spectrum disorderSelf-reported side effectsNeuroinflammatory diseasesSARS-CoV-2Multiple sclerosisSide effectsSARS-CoV-2 vaccine trialsCross-sectional observational studySafety/tolerability dataAsymptomatic control populationNeurologist-confirmed diagnosisRadiologic disease activityRecurrent neurologic symptomsSignificant vaccine hesitancyOptica spectrum disorderAntibody-mediated diseasesVaccine side effectsViral vector vaccinesReal-world evidenceMultiple academic centersNID patientsUnvaccinated patientsVaccines surveyDisease activityNeurologic events